ストックスクリーナーアプリを入手
2.34
2.18%
0.05
アフターアワーズ：
2.38
0.04
+1.71%
前日終値:
$2.29
開ける：
$2.32
24時間の取引高:
184.57K
Relative Volume:
1.13
時価総額：
$29.91M
収益：
-
当期純損益:
$-15.91M
株価収益率:
-1.6194
EPS:
-1.445
ネットキャッシュフロー:
$-15.07M
1週間 パフォーマンス:
-11.70%
1か月 パフォーマンス:
-20.41%
6か月 パフォーマンス:
-10.34%
1年 パフォーマンス:
-44.15%
1日の値動き範囲:
$2.13
$2.41
1週間の範囲:
$2.13
$2.83
52週間の値動き範囲:
$1.11
$4.7034
Lantern Pharma Inc Stock (LTRN) Company Profile
Compare LTRN vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
2.34 | 29.28M | 0 | -15.91M | -15.07M | -1.445 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-07 | 開始されました | H.C. Wainwright | Buy |
Lantern Pharma Inc (LTRN) 最新ニュース
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript - AOL.com
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI - GuruFocus
Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lantern Pharma Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LTRN) 2026-08-17 - Seeking Alpha
Lantern Pharma (LTRN) Slides 2.26% as Biotech Stock Approaches Critical $2.46 SupportKey Reversal Day - vinanet.vn
Lantern Pharma (LTRN) Updates Trial Design Amid Cash Raise; Mark - GuruFocus
Lantern Pharma (LTRN) Edges Up 0.76% to $2.65: Rangebound Trading Between Support and ResistanceBull Pennant - vinanet.vn
LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
Form 8K Lantern Pharma Inc For: 14 August By Investing.com - Investing.com Nigeria
LTRN: Static price chart | Lantern Pharma Inc. | US51654W1018 - marketscreener.com
Lantern Pharma Reports 46.2% Wider Q2 2026 Loss at -$0.57/Share - AlphaStreet
Lantern Pharma Releases Q2 2026 Financial Results - AlphaStreet
Lantern Pharma (LTRN) Advances AI-Driven Oncology Pipeline Amid Valuation Challenges - GuruFocus
Lantern Q2 2026 slides: operating loss drops 25%, LP-300 data strengthens - Investing.com Canada
Lantern Pharma Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Lantern Pharma posts q2 2026 loss miss as stock slips - Investing.com Nigeria
LTRN: AI-driven clinical pipeline and Open-Medicine AI spin-out drive growth amid reduced expenses - TradingView
LTRN: Open-Medicine AI spinout and clinical advances drove a leaner Q2 with reduced operating loss - TradingView
Lantern Pharma Q2 2026 Earnings Call Transcript - MarketBeat
BRIEF-Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update - Dailyhunt
Q2 2026 Lantern Pharma Inc Earnings Call Transcript - GuruFocus
Lantern Pharma Q2 EPS of $(0.57) misses estimate by 50% - scanx.trade
Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Lantern Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is Lantern Pharma Inc (LTRN) Facing Increased Losses After Q2 Ea - GuruFocus
Lantern Pharma Forms Open Medicine AI Subsidiary Business - tipranks.com
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price - TradingView
Lantern Pharma Inc. Q2 2026: Net income $(7.07M), EPS $(0.57) — 10-Q Summary - TradingView
Lantern Pharma Reports $7.1 Million Q2 Net Loss as LP-184 Trial Clears - Quiver Quantitative
Lung cancer trial narrows focus after 8.9-month progression-free result - Stock Titan
Lantern Pharma (LTRN) Earnings Date and Reports 2026 $LTRN - MarketBeat
Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits
Certain Common Stock of Lantern Pharma Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026. - marketscreener.com
Lantern Pharma Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Lantern Pharma (LTRN.US) will release its earnings report before market open on August 14. - Moomoo
Empery Asset Management, LP Acquires 1.3 Million Shares of Lantern Pharma Inc (LTRN) - GuruFocus
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET - Business Wire
LTRN Price History for Lantern Pharma Stock - Barchart.com
LTRN Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Lantern Pharma (LTRN): Empery Asset Management discloses 9.99% beneficial stake - Stock Titan
Lantern Pharma Spins Off Open-Medicine AI Platform - TipRanks
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - BioSpace
Lantern Pharma (LTRN) Establishes Open-Medicine AI to Expand Mul - GuruFocus
Lantern Pharma establishes Open-Medicine AI to commercialize multi-agent AI co-scientist platform - TradingView
Lantern Pharma spins out AI platform into Open-Medicine AI - Investing.com
Lantern Pharma spins out AI platform into Open-Medicine AI By Investing.com - Investing.com Canada
Lantern Pharma’s bladder cancer trial cleared by EMA - Investing.com Nigeria
Lantern Pharma (LTRN) Gains EMA Approval for Phase 1b/2 Trial in Bladder Cancer - GuruFocus
Two Tumor Markers Will Guide Lantern Pharma's Bladder Cancer Trial - Stock Titan
Lantern Pharma (LTRN) Slides 6.8% as Stock Tests Key Support at $2.47Wyckoff Upthrust - vinanet.vn
LTRN|Lantern Pharma Inc|Price:2.890|Chg%:+0.140 - TradingKey
Lantern Pharma Inc (LTRN) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):